Question: how much is bmy paying for celgene?
Answer: Bristol-Myers Squibb announce plans to buy Celgene in a cash and stock deal valued at $74 billion. Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share.